Abstract: This invention provides novel polypeptides that modulate activities of the replication and transcription activator (RTA) of Kaposi's sarcoma-associated herpesvirus (KSHV). The invention also provides methods for screening modulators of RTA activities. The methods comprise first screening test agents for modulators of an RTA-modulatory polypeptide and then further screening the identified modulating agents for modulators of RTA activities. The invention further provides methods and pharmaceutical compositions for treating diseases and conditions associated with infections of gammaherpesviruses.
Type:
Application
Filed:
August 17, 2004
Publication date:
June 9, 2005
Applicant:
IRM LLC
Inventors:
Josephine Harada, Christian Nelson, Sumit Chanda
Abstract: The present invention provides positioning devices the include one or more container stations that each comprise a support surface that is structured to position at least one multi-well container. Container stations are tiered relative to one another and/or rotationally coupled to support structures of the positioning devices. The invention also relates to systems and methods that include the positioning devices described herein.
Abstract: This invention provides methods for identifying novel SHMT modulators. The methods comprise first screening test agents for modulators of p38 activity and then further screening the identified modulating agents for modulators of SHMT enzyme activity. The invention further provides methods and pharmaceutical compositions for modulating cellular proliferation and for treating tumors using the novel SHMT modulators.
Abstract: Method for preparing rhodamine on a solid support and, in particular, methods for the economical preparation of rhodamine NHS ester are disclosed.
Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
Type:
Application
Filed:
August 18, 2004
Publication date:
May 26, 2005
Applicant:
IRM LLC
Inventors:
Hong Liu, Arnab Chatterjee, David Tully, Phillip Alper, Badry Bursulaya, Jianhua Guo, David Woodmansee, Daniel Mutnick, Donald Karanewsky, Yun He
Abstract: The present invention relates generally to sample assaying systems that include non-pressure-based fluid transfer probes. The non-pressure-based fluid transfer probes of the invention are typically utilized to transfer fluidic samples to sample assay containers or other supports for sample detection or imaging. The invention also provides various additional components that are optionally included in these systems, including container positioning devices, container storage components, and robotic devices among others. Pin tools and methods of assaying fluidic samples that utilize the systems of the invention are also provided.
Abstract: The invention provides multi-well containers that include membranes for performing various processes, including analytical and synthetic processes. Related systems, kits, and methods are also provided.
Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
Type:
Application
Filed:
August 18, 2004
Publication date:
May 19, 2005
Applicant:
IRM LLC
Inventors:
Hong Liu, Phillip Alper, Donald Karanewsky
Abstract: A method is provided which comprises: performing a plurality of fermentations, each fermentation in a different sample vessel; and performing a further processing step on the plurality of fermented samples where the sample is retained in the same sample vessel as the fermentation during the processing step.
Abstract: The present invention provides material removal heads and devices for noninvasively removing materials from the wells of multi-well plates. The material removal heads of the invention are structured to prevent cross-contamination among wells of multi-well plates as materials are removed from the plates. The invention also provides dispense heads and devices that include angled dispensers. Related systems, kits, and methods are additionally provided.
Type:
Application
Filed:
April 7, 2004
Publication date:
March 17, 2005
Applicant:
IRM, LLC
Inventors:
Kenneth Micklash, Robert Downs, Jim Chang, James Mainquist
Abstract: This invention provides methods of screening for compounds that inhibit herpesviral transcription and replication. The methods comprise screening test compounds for ability to enhance the activity of homeodomain transcription factor PDX1 in repressing transcription of herpesviral genes (e.g., the IE gene of cytomegalovirus). Transcriptional repression by PDX1 can be monitored using an expression vector comprising a reporter gene operably linked to a PDX1-binding, upstream transcription regulatory sequence of the herpesvirus. The invention further provides methods and pharmaceutical compositions for stimulating PDX1-mediated transcriptional repression in a subject and for treating diseases and conditions associated with herpesviral infection.
Type:
Application
Filed:
July 7, 2004
Publication date:
March 17, 2005
Applicant:
IRM LLC, a Delaware Limited Liability Company
Abstract: This invention provides novel methods for identifying modulators of transmembrane protease serine 6 (TMPRSS6). The methods comprise screening test agents for ability to modulate proteolysis of a pathogenic toxin substrate or a synthetic peptide substrate of TMPRSS6. The methods can further comprise screening the identified modulating agents for ability to inhibit infections of pathogens. Also provided in the invention are methods and pharmaceutical compositions for treating infections of pathogens whose toxins are proteolytically activated by TMPRSS6.
Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
Type:
Application
Filed:
June 10, 2004
Publication date:
March 3, 2005
Applicant:
IRM LLC
Inventors:
Hong Liu, David Tully, Phillip Alper, Robert Epple, Arnab Chatterjee, Michael Roberts
Abstract: This invention provides novel NF-AT-modulatory polypeptides. The invention also provides methods for screening modulators of NF-AT. The methods comprise first screening test agents for modulators of an NF-AT-modulatory polypeptide and then further screening the identified modulating agents for modulators of NF-AT. The invention further provides methods and pharmaceutical compositions for modulating NF-AT bioactivities in a cell and for treating diseases and conditions mediated by abnormal NF-AT activities.
Type:
Application
Filed:
December 10, 2003
Publication date:
March 3, 2005
Applicant:
IRM LLC, a Delaware Limited Liability Company
Inventors:
Suhaila White, Sumit Chanda, Jeremy Caldwell
Abstract: This invention provides methods for the solution-phase synthesis of arylbenzoxazoles. The methods involve condensation of aminophenols with benzaldehydes to form a Schiff base. The Schiff base is then induced to undergo oxidative cyclization in the presence of DDQ. The resulting arylbenzoxazoles can be separated from the reduced DDQ byproduct by treatment of reaction mixture with a strongly basic ion exchange resin.
Abstract: This invention provides novel Epo-modulating polypeptides. The invention also provides methods for screening modulators of Epo expression. The methods comprise first screening test agents for modulators of an Epo-modulating polypeptide and then further screening the identified modulating agents for modulators of Epo expression. The invention further provides methods and pharmaceutical compositions for modulating Epo expression in cells and for treating diseases and conditions due to Epo deficiency.
Type:
Application
Filed:
June 4, 2004
Publication date:
February 17, 2005
Applicant:
IRM LLC, a Delaware Limited Liability Company
Inventors:
Fred King, Sumit Chanda, Jeremy Caldwell, John Hogenesch
Abstract: The invention provides a novel class of compounds and compositions that are useful in the treatment or prevention of diseases or disorders associated with kinases, particularly GSK-3?, c-Abl, HER-1, HER-2, KDR, Flt-3, c-Raf-1, PDGFR-?, c-Kit, Flt-4, Flt-1, Tek, c-src, CDK1, PDK1, FGFR-1, FGFR-2, Fer, MAP3K13, EPHA7 and c-Met kinases. The invention further relates to the use of the compounds of the invention as potent inducers of neurogenesis in embryonic stem cells.
Type:
Application
Filed:
April 22, 2004
Publication date:
February 17, 2005
Applicants:
THE SCRIPPS RESEARCH INSTITUTE, IRM LLC
Inventors:
Sheng Ding, Tom Wu, Nathanael Gray, Peter Schultz
Abstract: This invention provides novel methods for modulating expression of glut4 and other genes involved in glucose metabolism, and methods for treating or ameliorating diabetes and related diseases. The methods comprise administering to cells in a subject an effective amount of an LXR agonist and thereby modulating expression of those genes that are important for glucose uptake or gluconeogenesis. The modulation will lead to increased uptake of glucose by cells in the subject and/or reduced glucose output in the liver, and accordingly ameliorate symptoms associated with, e.g., type II diabetes.
Type:
Application
Filed:
December 22, 2003
Publication date:
February 17, 2005
Applicants:
IRM LLC, The Regents of the University of California
Inventors:
Enrique Saez, Peter Tontonoz, Bryan Laffitte, Jing Li
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl.